Researchers developed models from patient material representing different types of Bladder cancer – the latest news review by BIOMEDICA CRO
Hundreds of chemical compounds were screened on cell cultures representing different stages and subtypes of Bladder cancer and several promising agents with inhibitory (growth-inhibiting) effects were identified during the study at MedUni Vienna.
One of these compounds, clofarabine, an antimetabolite currently used as a treatment for childhood leukemia, was studied in more detail. For this, the researchers developed models from patient material representing different types of Bladder cancer. In addition to “conventional” urothelial carcinomas, they were also able to establish an animal model for sarcomatoid carcinoma. This is a rare subtype of Bladder cancer, for which there is currently no effective chemotherapy.
“We found that clofarabine induced complete remission in mice with conventional urothelial carcinoma, while in the animals with sarcomatoid carcinomas it led to massive, sustained shrinkage of the tumors without causing any apparent side effects,” said first author Iris Ertl from the Department of Urology, describing the results.
The next steps will be clinical trials in which patients with metastatic Bladder cancer who, for various reasons, cannot be given cisplatin-based therapy will be given clofarabine prior to radical cystectomy (surgical removal of the urinary bladder).
Please find more information on the Medical University of Vienna website, news, article “Bladder cancer: therapeutically effective drugs identified”.
BIOMEDICA CRO provides scientists with diseased and normal blood, serum, plasma, tissues, urine samples, and other biofluids all over the world since 2017.
We have a good collection rate of oncology samples (Bladder cancer, Breast cancer, CRC, Prostate cancer, etc.) and also access to specimens from other disease areas.
Our team is proud to participate in preclinical trials, new biomarkers development and drugs discovery. We will be happy to cooperate once you need an additional source of biospecimens for your research.
Please email us office@biomedica-cro.com / LinkedIn to receive high-quality human biospecimens and associated data for your studies.
